Handelsavisen
prelaunch
Companies Healthcare 9544.SE
95
9544.SE Tadawul Healthcare Facilities & Services

9544.Se

$1,78
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
23,2 %
ROE
16,2 %
Net margin
20,7 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

Business. The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
16,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 9544.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 9544.SE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 9.3, indicating a high ability to meet short-term obligations. The liquidity_fpt metric further supports this, showing a robust cash and equivalents position of 20,595,360. The company's operating cash flow of 12,540,200 and free cash flow of 14,623,190 reinforce its financial flexibility.

    Profitability metrics show the company is performing well relative to industry standards. The return on equity of 16.25% and return on assets of 14.23% are strong indicators of efficient capital use and asset management. The operating income of 17,612,660 and net income of 15,753,370 reflect solid earnings performance.

    The company's revenue is concentrated in its core operations, with no disclosed segments or geographic breakdowns provided in the available data. This suggests a relatively undiversified revenue stream, which could pose a concentration risk if the core operations face any disruption.

    The company's growth trajectory is positive, with a strong revenue base of 76,061,680 and consistent profitability. While no specific growth rates are provided, the company's free cash flow and operating cash flow suggest a capacity for reinvestment and expansion.

    Risk factors are minimal, with low liquidity and dilution risk identified. The debt-to-equity ratio of 0.01 indicates a conservative capital structure, and no immediate filing-based liquidity or dilution flags were detected. The dilution potential is also low, with no near-term pressure expected.

    Recent events, including filings and transcripts, do not indicate any significant changes or risks to the company's operations. The company's financial health and operational performance remain stable, with no major disruptions reported in the latest available data.

    Key takeaways
    • The company has a strong liquidity position, supported by a high current ratio and substantial cash reserves.
    • Profitability metrics are robust, with high return on equity and return on assets.
    • The company's revenue is concentrated in its core operations, which may pose a concentration risk.
    • Growth is supported by strong cash flow and a conservative capital structure.
    • Risk factors are minimal, with low liquidity and dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,78
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $97.0M
    Net cash
    $19.2M
    Current ratio
    9.3
    Debt / equity
    0.0
    ROA
    14.2%
    ROE
    16.2%
    Cash conversion
    80.0%
    CapEx / revenue
    -4.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin23,2 %Above P75
    Net Margin20,7 %Best in class
    ROE16,2 %Above P75
    Capex / Rev-4,9 %Above median
    D/E0,01Above P75
    Cash Conv0,80Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 9544.SE Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    9544.SECanonical
    Tadawul · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage